CRL
Charles River Laboratories International, Inc. NYSE Listed Jun 23, 2000$181.94
Mkt Cap $9.0B
52w Low $132.58
51.3% of range
52w High $228.88
50d MA $170.37
200d MA $176.34
P/E (TTM)
-57.0x
EV/EBITDA
14.2x
P/B
2.6x
Debt/Equity
1.0x
ROE
-4.6%
P/FCF
19.5x
RSI (14)
—
ATR (14)
—
Beta
1.62
50d MA
$170.37
200d MA
$176.34
Avg Volume
1.0M
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
251 Ballardvale Street · Wilmington, MA 01887 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 181.73 | +4.2% | -0.0% | — | — | — | — | — |
| Feb 18, 2026 | AMC | 2.33 | 2.39 | +2.6% | 158.00 | -2.5% | +3.9% | +2.8% | -3.2% | +1.6% | +0.9% | — |
| Nov 5, 2025 | AMC | 2.32 | 2.43 | +4.7% | 167.70 | +0.0% | +1.9% | -1.7% | +0.5% | +2.7% | -1.2% | — |
| Aug 6, 2025 | AMC | 2.50 | 3.12 | +24.8% | 150.33 | +2.0% | -0.4% | -0.7% | +0.1% | +2.6% | +1.5% | — |
| May 7, 2025 | AMC | 2.06 | 2.34 | +13.6% | 136.97 | +2.7% | +3.2% | -1.8% | +3.1% | +0.7% | -3.5% | — |
| Feb 19, 2025 | AMC | 2.50 | 2.66 | +6.4% | 165.00 | +0.0% | -1.7% | +0.5% | +4.6% | -2.0% | +0.5% | — |
| Nov 6, 2024 | AMC | 2.42 | 2.59 | +7.0% | 214.20 | +0.7% | -1.8% | +2.4% | +2.5% | -2.2% | -4.4% | — |
| Aug 7, 2024 | AMC | 2.39 | 2.80 | +17.2% | 199.96 | -4.2% | +1.0% | -0.5% | -3.3% | +4.7% | -2.4% | — |
| May 9, 2024 | AMC | 2.06 | 2.27 | +10.2% | 230.09 | +0.1% | -0.9% | +0.1% | +1.9% | -0.1% | -3.4% | — |
| Feb 14, 2024 | AMC | 2.39 | 2.46 | +2.9% | 245.12 | -1.2% | +0.1% | -0.2% | -2.5% | +0.9% | +2.4% | — |
| Nov 8, 2023 | AMC | 2.35 | 2.72 | +15.7% | 175.97 | +0.7% | -3.7% | +1.5% | -1.1% | +4.9% | +5.2% | — |
| Aug 9, 2023 | AMC | 2.63 | 2.69 | +2.3% | 215.80 | +0.1% | +0.8% | -1.4% | +1.1% | -3.1% | -3.9% | — |
| May 11, 2023 | AMC | 2.59 | 2.78 | +7.3% | 195.75 | +0.6% | -2.3% | +0.6% | -2.2% | +4.6% | +1.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 14 | Barclays | Maintains | Overweight → Overweight | — | $178.34 | $181.90 | +2.0% | +0.5% | +0.7% | -2.0% | +3.9% | +0.9% |
| Apr 13 | JP Morgan | Maintains | Neutral → Neutral | — | $175.65 | $177.47 | +1.0% | +1.5% | +0.5% | +0.7% | -2.0% | +3.9% |
| Feb 25 | UBS | Maintains | Neutral → Neutral | — | $166.06 | $169.91 | +2.3% | +0.9% | +4.7% | +1.7% | +0.1% | -1.6% |
| Feb 20 | TD Cowen | Maintains | Buy → Buy | — | $164.24 | $162.54 | -1.0% | +2.8% | -3.2% | +1.6% | +0.9% | +4.7% |
| Feb 20 | Mizuho | Maintains | Neutral → Neutral | — | $164.24 | $162.54 | -1.0% | +2.8% | -3.2% | +1.6% | +0.9% | +4.7% |
| Feb 19 | Evercore ISI | Maintains | Outperform → Outperform | — | $158.00 | $154.09 | -2.5% | +3.9% | +2.8% | -3.2% | +1.6% | +0.9% |
| Feb 19 | Barclays | Maintains | Overweight → Overweight | — | $158.00 | $154.09 | -2.5% | +3.9% | +2.8% | -3.2% | +1.6% | +0.9% |
| Jan 16 | Citigroup | Maintains | Buy → Buy | — | $223.47 | $223.43 | -0.0% | -1.7% | -0.7% | +3.9% | -1.2% | -2.0% |
| Jan 13 | Evercore ISI | Maintains | Outperform → Outperform | — | $218.82 | $221.66 | +1.3% | +0.1% | -1.2% | +3.3% | -1.7% | -0.7% |
| Dec 18 | Mizuho | Maintains | Neutral → Neutral | — | $195.98 | $197.32 | +0.7% | -1.1% | +1.7% | +3.0% | -0.1% | +0.1% |
| Dec 15 | JP Morgan | Maintains | Neutral → Neutral | — | $193.03 | $197.08 | +2.1% | +2.7% | -1.5% | +0.4% | -1.1% | +1.7% |
| Dec 15 | Barclays | Maintains | Overweight → Overweight | — | $193.03 | $197.08 | +2.1% | +2.7% | -1.5% | +0.4% | -1.1% | +1.7% |
| Nov 11 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $168.97 | $169.70 | +0.4% | +2.7% | -1.2% | -1.3% | -0.8% | -3.0% |
| Nov 10 | TD Cowen | Maintains | Buy → Buy | — | $168.05 | $167.14 | -0.5% | +0.5% | +2.7% | -1.2% | -1.3% | -0.8% |
| Nov 6 | Barclays | Maintains | Overweight → Overweight | — | $167.70 | $167.72 | +0.0% | +1.9% | -1.7% | +0.5% | +2.7% | -1.2% |
| Nov 6 | JP Morgan | Maintains | Neutral → Neutral | — | $167.70 | $167.72 | +0.0% | +1.9% | -1.7% | +0.5% | +2.7% | -1.2% |
| Nov 6 | Baird | Upgrade | Neutral → Outperform | — | $167.70 | $167.72 | +0.0% | +1.9% | -1.7% | +0.5% | +2.7% | -1.2% |
| Oct 17 | Mizuho | Maintains | Neutral → Neutral | — | $174.95 | $173.16 | -1.0% | +2.0% | +3.1% | +2.2% | -0.7% | +2.1% |
| Oct 6 | William Blair | Upgrade | Market Perform → Outperform | — | $177.33 | $178.15 | +0.5% | -1.3% | -2.8% | +2.0% | -0.8% | -3.0% |
| Oct 3 | Evercore ISI | Maintains | Outperform → Outperform | — | $175.36 | $176.00 | +0.4% | +1.1% | -1.3% | -2.8% | +2.0% | -0.8% |
| Oct 2 | Barclays | Upgrade | Equal Weight → Overweight | — | $170.48 | $173.25 | +1.6% | +2.9% | +1.1% | -1.3% | -2.8% | +2.0% |
| Sep 9 | Jefferies | Upgrade | Hold → Buy | — | $162.00 | $167.50 | +3.4% | -2.9% | -2.6% | +4.2% | -4.3% | -0.4% |
| Aug 8 | Evercore ISI | Maintains | Outperform → Outperform | — | $149.78 | $150.49 | +0.5% | -0.7% | +0.1% | +2.6% | +1.5% | +0.5% |
| Aug 7 | Barclays | Maintains | Equal Weight → Equal Weight | — | $150.33 | $153.37 | +2.0% | -0.4% | -0.7% | +0.1% | +2.6% | +1.5% |
| Aug 7 | JP Morgan | Maintains | Neutral → Neutral | — | $150.33 | $153.37 | +2.0% | -0.4% | -0.7% | +0.1% | +2.6% | +1.5% |
| Jul 9 | Evercore ISI | Maintains | Outperform → Outperform | — | $158.39 | $162.89 | +2.8% | +0.4% | +3.0% | -2.6% | -0.9% | -2.3% |
| Jul 9 | Citigroup | Upgrade | Neutral → Buy | — | $158.39 | $162.89 | +2.8% | +0.4% | +3.0% | -2.6% | -0.9% | -2.3% |
| May 23 | Redburn Atlantic | Upgrade | Neutral → Buy | — | $135.60 | $134.21 | -1.0% | +0.8% | +1.4% | -1.7% | +1.1% | -1.5% |
| May 8 | Baird | Maintains | Neutral → Neutral | — | $136.97 | $140.70 | +2.7% | +3.2% | -1.8% | +3.1% | +0.7% | -3.5% |
| May 8 | Barclays | Maintains | Equal Weight → Equal Weight | — | $136.97 | $140.70 | +2.7% | +3.2% | -1.8% | +3.1% | +0.7% | -3.5% |
| Apr 10 | Barclays | Maintains | Equal Weight → Equal Weight | — | $139.07 | $136.27 | -2.0% | -28.1% | -0.2% | +6.9% | -0.6% | -1.6% |
| Apr 9 | Mizuho | Maintains | Neutral → Neutral | — | $123.61 | $121.71 | -1.5% | +12.5% | -28.1% | -0.2% | +6.9% | -0.6% |
| Mar 21 | Goldman Sachs | Downgrade | Buy → Neutral | — | $165.35 | $162.94 | -1.5% | +1.2% | -0.2% | -3.4% | -1.9% | -0.1% |
| Mar 4 | Citigroup | Upgrade | Sell → Neutral | — | $163.50 | $164.07 | +0.3% | +0.5% | +2.0% | +1.0% | +3.9% | -0.5% |
| Mar 3 | Redburn Atlantic | Upgrade | Sell → Neutral | — | $165.31 | $165.89 | +0.4% | -1.1% | +0.5% | +2.0% | +1.0% | +3.9% |
| Feb 20 | JP Morgan | Maintains | Neutral → Neutral | — | $165.00 | $165.00 | +0.0% | -1.7% | +0.5% | +4.6% | -2.0% | +0.5% |
| Feb 20 | Baird | Maintains | Neutral → Neutral | — | $165.00 | $165.00 | +0.0% | -1.7% | +0.5% | +4.6% | -2.0% | +0.5% |
| Feb 20 | Barclays | Maintains | Equal Weight → Equal Weight | — | $165.00 | $165.00 | +0.0% | -1.7% | +0.5% | +4.6% | -2.0% | +0.5% |
| Feb 18 | Barclays | Maintains | Equal Weight → Equal Weight | — | $151.99 | $151.59 | -0.3% | +1.6% | +6.9% | -1.7% | +0.5% | +4.6% |
| Feb 5 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $163.12 | $165.84 | +1.7% | +1.7% | +0.2% | -1.5% | -2.4% | -3.1% |
| Feb 3 | JP Morgan | Maintains | Neutral → Neutral | — | $164.76 | $161.80 | -1.8% | -1.9% | +0.9% | +1.7% | +0.2% | -1.5% |
| Jan 23 | Goldman Sachs | Maintains | Buy → Buy | — | $168.22 | $168.90 | +0.4% | -0.8% | -1.1% | +0.5% | -1.3% | -1.2% |
| Jan 22 | William Blair | Downgrade | Outperform → Market Perform | — | $169.81 | $167.87 | -1.1% | -0.9% | -0.8% | -1.1% | +0.5% | -1.3% |
| Jan 17 | UBS | Downgrade | Buy → Neutral | — | $165.80 | $165.41 | -0.2% | -1.4% | +3.9% | -0.9% | -0.8% | -1.1% |
| Jan 14 | William Blair | Maintains | Outperform → Outperform | — | $190.14 | $179.87 | -5.4% | -6.3% | -2.3% | -4.7% | -1.4% | +3.9% |
| Dec 16 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $190.46 | $189.72 | -0.4% | -0.2% | -0.4% | -3.3% | -0.6% | +2.0% |
| Dec 13 | BofA Securities | Maintains | Neutral → Neutral | — | $194.27 | $194.17 | -0.1% | -2.0% | -0.2% | -0.4% | -3.3% | -0.6% |
| Nov 11 | TD Cowen | Maintains | Hold → Hold | — | $215.39 | $217.67 | +1.1% | +2.5% | -2.2% | -4.4% | -4.7% | -4.7% |
| Nov 7 | Evercore ISI | Maintains | In Line → In Line | — | $214.20 | $215.75 | +0.7% | -1.8% | +2.4% | +2.5% | -2.2% | -4.4% |
| Nov 7 | UBS | Maintains | Buy → Buy | — | $214.20 | $215.75 | +0.7% | -1.8% | +2.4% | +2.5% | -2.2% | -4.4% |
No insider trades available.
8-K · 7.01
! Medium
Charles River Laboratories International, Inc. -- 8-K 7.01: Regulation FD Disclosure
Charles River Laboratories plans to divest its CDMO and Cell Solutions businesses, eliminating revenue streams from advanced therapy manufacturing services and cellular materials, potentially impacting investor returns.
Feb 25
8-K
Charles River Laboratories International, Inc. -- 8-K Filing
Charles River Laboratories' Q4 2025 revenue declined 0.8% year-over-year to $994.2 million, signaling modest top-line pressure that investors should monitor alongside management's 2026 guidance.
Feb 18
8-K · 5.02
!!! Very High
Charles River Laboratories International, Inc. -- 8-K 5.02: Executive Change
Charles River Laboratories appointed Glenn Coleman as Corporate Executive Vice President and Chief Financial Officer, effective April 6, 2026, signaling leadership stability in financial operations.
Feb 18
Data updated apr 25, 2026 3:15am
· Source: massive.com